Zacks Research Has Negative Outlook for Qiagen Q1 Earnings

Qiagen (NYSE:QGEN) – Research analysts at Zacks Research decreased their Q1 2025 EPS estimates for shares of Qiagen in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will earn $0.48 per share for the quarter, down from their previous estimate of $0.50. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.58 EPS, FY2025 earnings at $2.25 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.67 EPS and FY2026 earnings at $2.40 EPS.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%.

A number of other equities research analysts also recently commented on QGEN. Baird R W downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Morgan Stanley reissued an “equal weight” rating and issued a $46.67 price objective (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Robert W. Baird downgraded shares of Qiagen from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $52.00 to $42.00 in a research report on Wednesday, February 19th. UBS Group dropped their target price on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $52.50 target price (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and an average target price of $47.71.

Qiagen Trading Down 1.0 %

Shares of NYSE:QGEN opened at $37.85 on Monday. Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30. The company’s 50 day moving average is $42.51 and its two-hundred day moving average is $42.80. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market cap of $8.40 billion, a PE ratio of 105.39, a P/E/G ratio of 2.39 and a beta of 0.36.

Institutional Trading of Qiagen

A number of large investors have recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Qiagen during the 4th quarter worth $95,746,000. Forum Financial Management LP acquired a new stake in Qiagen during the 4th quarter worth $221,000. GF Fund Management CO. LTD. acquired a new stake in Qiagen during the 4th quarter worth $216,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Qiagen by 6.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 492,302 shares of the company’s stock worth $21,922,000 after purchasing an additional 30,989 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in Qiagen by 30.0% during the 4th quarter. Two Sigma Advisers LP now owns 197,112 shares of the company’s stock worth $8,777,000 after purchasing an additional 45,505 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.